The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma by unknown
Cho et al. Journal of Ovarian Research  (2015) 8:2 
DOI 10.1186/s13048-015-0129-3RESEARCH Open AccessThe expression of DBC1/CCAR2 is associated with
poor prognosis of ovarian carcinoma
Dong Hyu Cho1, Ho Sung Park2, See-Hyoung Park3, Kyoung Min Kim2, Myoung Ja Chung2, Woo Sung Moon2,
Myoung Jae Kang2 and Kyu Yun Jang2*Abstract
Background: Recent reports have shown that deleted in breast cancer 1 (DBC1/CCAR2) is an indicator of poor
prognosis of various human cancers. However, its expression in ovarian carcinoma has not been reported.
Methods: We investigated the immunohistochemical expression of DBC1 and BRCA1 and their prognostic significance
in 104 ovarian carcinomas. Survival analyses were performed according to the Kaplan-Meier method, as well as
univariate and multivariate Cox proportional hazard regression analysis.
Results: Positive expression of DBC1 and BRCA1 were seen in 63% (66/104) and 44% (46/104) of overall
ovarian carcinomas, respectively. DBC1 expression was significantly associated with advanced clinicopathological
factors such as high tumor stage, latent distant metastasis, platinum-resistance, elevated serum levels of CA125, high
histologic grade, and BRCA1 expression. In the histological subtypes of ovarian carcinomas, DBC1 expression was more
common in serous carcinoma (72%, 54/75) than mucinous carcinoma (15%, 3/20). BRCA1 expression was significantly
associated with latent distant metastasis, platinum-resistance, and higher histologic grade. In addition, DBC1 expression
was significantly associated with shorter overall survival (OS) and relapse-free survival (RFS) in 104 ovarian carcinomas
(OS; P < 0.001, RFS; P < 0.001) and 63 high-grade serous carcinomas (OS; P = 0.008, RFS; P = 0.023) by univariate analysis.
BRCA1 expression was significantly associated with OS and RFS in 104 ovarian carcinomas (OS; P = 0.005, RFS; P = 0.002)
and 75 serous carcinomas (OS; P = 0.047, RFS; P = 0.038) by univariate analysis. Moreover, DBC1 expression was an
independent prognostic indicator for OS in both 104 ovarian carcinomas (P = 0.021) and 63 high-grade serous
carcinomas (P = 0.011) by multivariate analysis.
Conclusions: These results indicate that the expression of DBC1 and BRCA1 are closely related with in the
progression of ovarian carcinomas and may have clinical utility in the prediction of prognosis of ovarian
carcinomas. Especially, DBC1 expression could be employed as a significant prognostic indicator for ovarian
carcinomas especially in high-grade serous carcinomas.
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Deleted in breast cancer 1/cell cycle and apoptosis regu-
lator 2 (DBC1/CCAR2) was named by its deletion at a
region 8p22 in breast cancer. Thereafter, DBC1 was re-
designated CCAR2 to eliminate possible confusion with
deleted in bladder cancer 1 and because it has partial se-
quence homology to CCAR1. The deletion of DBC1 in
breast cancer suggested it may have a role as a tumor* Correspondence: kyjang@chonbuk.ac.kr
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unless otherwise stated.suppressor [1]. Based on data of cBio Cancer Genomics
Portal (http://www.cbioportal.org), the deletion of DBC1
has been reported in 2.5% (8/316) to 7.7% (24/311) of
ovarian serous carcinomas [2,3]. Especially, the inhibitory
role of DBC1 on SIRT1 supported the possibility that
DBC1 could be tumor suppressor because SIRT1 inacti-
vates various tumor suppressors, especially p53 [4,5]. How-
ever, these findings were followed by conflicting reports,
which cast doubt on whether DBC1 is tumor suppressor.
In human cancers, the deletion of DBC1 was not a com-
mon phenomenon and the balance between SIRT1 and
DBC1 was disrupted in human cancers [6]. When theis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Cho et al. Journal of Ovarian Research  (2015) 8:2 Page 2 of 11interaction between SIRT1 and DBC1 is week, the de-
pletion of DBC1 makes cells susceptible to UV-induced
genotoxic stress [7]. Also, DBC1 inhibits senescence of
premalignant cells by disrupting the SUV39H1-SIRT1
complex [8]. Moreover, the expression of both DBC1 and
SIRT1 were correlated with advanced clinicopathological
characteristics and poor prognosis of human malignant tu-
mors [9-16]. In addition, it has been shown that DBC1 has
multiple functions involved in the regulation of cell survival,
energy metabolism, and intracellular signal transduction
[8,12,17-21]. Therefore, DBC1 might have its own role in
tumorigenesis in addition to an inhibitory role for SIRT1.
The tumorigenic role of DBC1, although controversial,
is supported by its role in the inhibition of tumor sup-
pressors [8,22] and activation of nuclear receptors with
tumorigenic potential [21]. DBC1 inhibits the tumor
suppressor BRCA1 by binding to the BRCT domain in
breast cancer [22]. Defect of BRCA1/2 is involved in the
development of ovarian carcinomas and defects in
BRCA1/2 are associated with the resistance to platinum-
based chemotherapy in ovarian carcinomas [23,24]. There-
fore, there is a possibility that DBC1 may be involved in
BRCA1/2-related progression of ovarian carcinomas. In
addition, inhibition of DBC1 reduced the proliferation
and invasive potential of gastric cancer cells and squa-
mous cell carcinoma cells [12,20]. The decrease of tumor
invasiveness with inhibition of DBC1 was associated with
a decrease in epithelial-mesenchymal transition (EMT)
signaling [12].
The role of DBC1 as a co-activator of hormone recep-
tors raised the possibility that DBC1 could promote the
tumorigenesis of hormone-dependent organs [18,19,21].
In breast carcinoma, DBC1 is expected to be an indica-
tor of poor prognosis and might be involved in resist-
ance to the estrogen receptor-targeted therapies [14].
However, there has been no study to date on the role of
DBC1 in ovarian tumorigenesis, its relation to BRCA1/2,
and the prognostic significance of DBC1 in ovarian can-
cers. Therefore, in this study, we evaluated the immuno-
histochemical expression of DBC1 and BRCA1 and their
prognostic significance in 104 ovarian carcinomas.
Methods
Patients and tissue samples
One hundred and four ovarian carcinomas diagnosed
between November 1996 and August 2008, and the ori-
ginal histologic slides, tissue blocks, and clinical infor-
mation were available were included in the present
study. The age of the patients ranged from 21 to 82 years
(median; 54 years). All patients received staging opera-
tions and 83 patients received platinum- and taxoid-
based adjuvant chemotherapy. Among the 83 patients,
platinum-resistance was evaluable in 82 patients and 62
patients were sensitive to platinum-based chemotherapyand 20 patients showed platinum-resistance. Platinum-
resistance was evaluated according to the standard
Gynecologic Oncology Group criteria [25]. The patients
who experienced recurrence or progression of ovarian
cancer within the six months of platinum-based chemo-
therapy were included in platinum-resistant group. Among
the 104 ovarian carcinoma patients, 39 patients experi-
enced relapse and 50 patients died from ovarian carcinoma
at the endpoint of follow-up. The five- and ten-year overall
survival (OS) rates were 57% and 50%, respectively. This
study was approved by the institutional review board of
Chonbuk National University Hospital. Informed consent
was provided according to the Declaration of Helsinki.
All histologic slides and clinicopathologic factors were
reviewed according to the criteria of the World Health
Organization classification of tumors of female repro-
ductive organs [26]. The ovarian carcinomas included in
this study, according to the histologic types, were 75 ser-
ous carcinomas (12 low-grade serous carcinomas and 63
high-grade serous carcinomas), 20 mucinous carcinomas,
5 endometrioid carcinomas, 3 clear cell carcinomas, and
one malignant Brenner tumor. Tumor stage was reviewed
according to the guidelines of the tumor, node, and metas-
tasis staging system of the American Joint Committee
on Cancer [27]. Thereafter, the ovarian carcinomas
were grouped according to their age (<60 years versus ≥
60 years), tumor stage (I and II versus III and IV), tumor
size (≤10 cm versus > 10 cm), lymph node metastasis (ab-
sence versus presence), presence of ascites (absence versus
presence), bilaterality (unilateral versus bilateral), presence
of latent distant metastasis during follow-up (absence
versus presence), pre-operative serum level of CA19-9
(normal versus elevated, reference value; 0 - 37 U/ml),
pre-operative serum level of CA125 (normal versus ele-
vated, reference value; 0 - 35 U/ml), and histologic grade
(low; grade 1 versus high; grade 2 and 3). The duration
of follow-up ranged from one to 193 months (median;
70 months).
Establishment of tissue microarray and
immunohistochemical staining
Tissue microarray (TMA) established from the most rep-
resentative solid area with highest histologic grade after
review of original H&E slides. One 5 mm tissue core per
case was used for the construction of a TMA. Immunohis-
tochemical staining for DBC1 (1:100, Bethyl Laboratories,
Mongomery, TX) and BRCA1 (1:100, Abcam, Cambridge,
MA) was performed on 4 μm thick sections on TMA
slides. The tissue sections underwent a microwave antigen
retrieval procedure in pH 6.0 sodium citrate buffer
for 20 minutes. Immunohistochemical analysis was per-
formed by two pathologists (KYJ and KMK) by consensus,
without knowledge of the clinicopathological information.
For the evaluation of the immunohistochemical staining
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was used [28]. The staining intensity was scored as 0 (no
staining), 1 (weak staining), 2 (intermediate staining), or 3
(strong staining). The area of staining was scored as 0 (no
staining), 1 (1% of the cells stained positive), 2 (2-10% of
the cells stained positive), 3 (11-33% of cells stained posi-
tive), 4 (34-66% of cells stained positive), or 5 (67-100% of
cells stained positive). Thereafter, the sum score was ob-
tained by adding the intensity score and staining area
score [13,29], to give maximum sum score of eight and a
minimum sum score of zero.
Statistical analysis
The cut-off point of the immunohistochemical staining
score for DBC1 and BRCA1 expression was determined
by receiver operating characteristic curve analysis at the
highest positive likelihood ratio point for the event of
OS. The cut-off points for the sum score for DBC1 and
BRCA1 were seven and six, respectively. The immuno-
staining for DBC1 was considered positive when the sum
score was greater than or equal to seven and BRCA1 ex-
pression was considered positive when the sum score was
greater than or equal to six. The endpoint of interest was
OS and relapse-free survival (RFS). The endpoint of
follow-up was the date of last contact or date of death of
patients through August 2013. OS was calculated as the
time from the date of diagnosis to the date of last contact
or death from ovarian carcinomas. The patients who were
alive at last contact were treated as censored for OS ana-
lysis. RFS calculated from the date of diagnosis to the date
of last contact, local relapse, latent metastasis, or death
from ovarian carcinomas. The patients who were alive at
last contact without experience of local relapse or latent
metastasis were treated as censored for RFS analysis.
Survival analyses were performed according to the
Kaplan-Meier method, and univariate and multivariateFigure 1 Immunohistochemical expression of DBC1/CCAR2 and BRCA
nuclei of the tumor cells. BRCA1 is expressed both in the cytoplasm and nuCox proportional hazard regression analysis. The associ-
ation between immunohistochemical positivity of DBC1
expression and other clinicopathological factors poten-
tially predictive of prognosis were analyzed using Pearson’s
chi-square test. SPSS software (version 20.0) was used
throughout and P-values less than 0.05 were considered
statistically significant.
Results
Association of DBC1 and BRCA1 expression with
clinicopathologic characteristics of ovarian carcinoma
patients
As shown in Figure 1, DBC1 was expressed exclusively in
the nuclei of tumor cells and nuclear expression was eval-
uated for the evaluation of DBC1. BRCA1 was expressed
in both the cytoplasm and nuclei; however, we have evalu-
ated only for the nuclear expression [30,31]. The asso-
ciations between the expression of DBC1, BRCA1, and
variable clinicopathologic features are summarized in
Table 1. Positive expression of DBC1 and BRCA1 were
seen in 63% (66/104) and 44% (46/104) of overall ovarian
carcinomas, respectively. Expression of DBC1 was signifi-
cantly associated with higher tumor stage (P = 0.015),
bilateral tumors (P = 0.008), latent distant metastasis (P =
0.016), platinum-resistance (P = 0.016), higher pre-operative
serum level of CA125 (P = 0.004), higher histologic grade
(P < 0.001), histologic type of ovarian carcinoma (P <
0.001), and BRCA1 expression (P < 0.001). DBC1 was
expressed in 72% (54/75) of serous carcinoma and 100%
of endometrioid carcinoma (5/5), clear cell carcinoma
(3/3), and the malignant Brenner tumor (1/1). How-
ever, only 15% (3/20) of mucinous carcinoma were
positive for DBC1. BRCA1 expression was significantly
associated with latent distant metastasis (P = 0.012),
platinum-resistance (P = 0.014), and higher histologic
grade (P = 0.007).1 in ovarian carcinomas. DBC1/CCAR2 is primarily expressed in the
clei of the tumor cells. Original magnification; ×400.
Table 1 Clinicopathological variables and the expression of DBC1 and BRCA1 in ovarian carcinomas
Characteristics No. Overall ovarian car cinomas No. Serous c Arcinomas
DBC1+ P BRCA1+ P DBC1+ P BRCA1+ P
Age, y <60 71 41 (58%) 0.076 28 (39%) 0.149 45 29 (64%) 0.074 20 (44%) 0.450
≥60 33 25 (76%) 18 (55%) 30 25 (83%) 16 (53%)
Stage I & II 52 27 (52%) 0.015 21 (40%) 0.430 29 18 (62%) 0.128 13 (45%) 0.662
III & IV 52 39 (75%) 25 (48%) 46 36 (78%) 23 (50%)
Tumor size, cm ≤10 68 48 (71%) 0.038 31 (46%) 0.702 56 40 (71%) 0.850 26 (46%) 0.64
>10 36 18 (50%) 15 (42%) 19 14 (74%) 10 (53%)
LN metastasis Absence 84 50 (60%) 0.087 37 (44%) 0.939 56 39 (70%) 0.435 28 (50%) 0.552
Presence 20 16 (80%) 9 (45%) 19 15 (79%) 8 (42%)
Ascites Absence 71 41 (58%) 0.076 28 (39%) 0.149 45 31 (69%) 0.462 18 (40%) 0.089
Presence 33 25 (76%) 18 (55%) 30 23 (77%) 18 (60%)
Bilaterality Unilateral 59 31 (53%) 0.008 24 (41%) 0.404 34 21 (62%) 0.072 16 (47%) 0.882
Bilateral 45 35 (78%) 22 (49%) 41 33 (80%) 20 (49%)
LD Meta Absence 76 43 (57%) 0.016 28 (37%) 0.012 52 34 (65%) 0.055 21 (40%) 0.047
Presence 28 23 (82%) 18 (64%) 23 20 (87%) 15 (65%)
Platinum-resistance Absence 62 38 (61%) 0.016 21 (34%) 0.014 48 32 (67%) 0.008 19 (40%) 0.043
Presence 20 18 (90%) 13 (65%) 16 16 (100%) 11 (69%)
CA19-9 Normal 66 47 (71%) 0.060 32 (48%) 0.158 50 39 (78%) 0.341 26 (52%) 0.156
Elevated 17 8 (47%) 5 (29%) 8 5 (63%) 2 925%)
CA125 Normal 18 7 (39%) 0.004 5 (28%) 0.121 7 4 (57%) 0.249 4 (57%) 0.630
Elevated 75 56 (75%) 36 (48%) 61 47 (77%) 29 (48%)
Histologic grade Low (1) 27 5 (19%) <0.001 6 (22%) 0.007 12 4 (33%) 0.001 4 (33%) 0.267
High (2 & 3) 77 61 (79%) 40 (52%) 63 50 (79%) 32 (51%)
Histologic type Serous 75 54 (72%) <0.001 36 (48%) 0.254
Mucinous 20 3 (15%) 5 (25%)
Endometrioid 5 5 (100%) 3 (60%)
Clear cell 3 3 (100%) 1 (33%)
Malignant Brenner 1 1 (100%) 1 (100%)
BRCA1 Negative 58 28 (48%) <0.001 39 22 (56%) 0.002
Positive 46 38 (83%) 36 32 (89%)
LN; lymph node, LD Meta; latent distant metastasis.
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Various histologic types of ovarian carcinomas with
different biologic and clinical background were included
in this study. Thus, we did additional analysis accord-
ing to the histologic types, especially for the serous
carcinoma. Among the 75 serous carcinomas, DBC1
expression was significantly associated with higher histo-
logic grade (P = 0.001) and platinum-resistance (P = 0.008)
and showed a slight association of borderline signifi-
cance with bilateral tumor (P = 0.072) and presence of
latent distant metastasis (P = 0.055). BRCA1 expression
was significantly associated with latent distant metas-
tasis (P = 0.047) and platinum-resistance (P = 0.008)
(Table 1).Expression of DBC1 and BRCA1 correlate with reduced
overall survival and relapse-free survival in ovarian
carcinomas by univariate analysis
Univariate analysis for the OS and RFS of the variable
clinicopathological factors and DBC1 and BRCA1 expres-
sion in ovarian carcinomas are shown in Table 2. Among
the 104 general cases of ovarian carcinoma, older age of
the patients (OS; P < 0.001, RFS; P = 0.003), higher tumor
stage (OS; P < 0.001, RFS; P < 0.001), presence of ascites
(OS; P = 0.006, RFS; P = 0.017), increased pre-operative
serum level of CA125 (OS; P = 0.013, RFS; P = 0.004),
histologic grade (OS; P = 0.005, RFS; P < 0.001), DBC1
expression (Log-rank, OS; P < 0.001, RFS; P < 0.001), and
BRCA1 expression (Log-rank, OS; P = 0.003, RFS; P =
Table 2 Univariate Cox regression analyses for overall survival and relapse-free survival in ovarian carcinomas
Characteristics No. OS RFS
HR (95% CI) P HR (95% CI) P
Overall ovarian carcinomas (n = 104)
Age, y, ≥ 60 (vs < 60) 33/104 2.686 (1.535-4.698) <0.001 2.157 (1.299-3.582) 0.003
Stage, III & IV (vs I & II) 52/104 3.579 (1.917-6.681) <0.001 3.930 (2.245-6.878) <0.001
Tumor size, cm, > 10 (vs≤ 10) 36/104 0.524 (0.274-1.004) 0.051 0.649 (0.375-1.125) 0.123
LN metastasis, presence (vs absence) 20/104 1.568 (0.831-2.959) 0.165 1.889 (1.076-3.314) 0.027
Ascites, presence (vs absence) 33/104 1.997 (1.140-3.498) 0.016 1.854 (1.116-3.077) 0.017
Bilaterality, bilateral (vs unilateral) 45/104 1.647 (0.943-2.876) 0.080 1.995 (1.204-3.303) 0.007
CA19-9, elevated (vs normal) 17/83 0.753 (0.314-1.806) 0.525 0.811 (0.379-1.733) 0.588
CA125, elevated (vs normal) 75/93 4.451 (1.376-14.393) 0.013 4.458 (1.609-12.351) 0.004
Histologic grade, high (vs low) 77/104 3.762 (1.491-9.496) 0.005 3.794 (1.719-8.374) <0.001
DBC1, positive (vs negative) 66/104 3.474 (1.684-7.166) <0.001 3.007 (1.624-5.567) <0.001
BRCA1, positive (vs negative) 46/104 2.263 (1.287-3.979) 0.005 2.254 (1.359-3.739) 0.002
Serous carcinomas (n = 75)
Age, y, ≥ 60 (vs < 60) 30/75 2.601 (1.411-4.796) 0.002 1.926 (1.116-3.323) 0.019
Stage, III & IV (vs I & II) 46/75 2.263 (1.131-4.528) 0.021 2.809 (1.485-5.312) 0.001
Tumor size, cm, > 10 (vs≤ 10) 19/75 0.625 (0.289-1.352) 0.233 0.817 (0.436-1.532) 0.529
LN metastasis, presence (vs absence) 19/75 1.200 (0.613-2.349) 0.595 1.502 (0.831-2.714) 0.178
Ascites, presence (vs absence) 30/75 1.793 (0.977-3.291) 0.060 1.645 (0.953-2.839) 0.074
Bilaterality, bilateral (vs unilateral) 41/75 1.200 (0.647-2.224) 0.563 1.423 (0.813-2.492) 0.217
CA19-9, elevated (vs normal) 8/58 0.679 (0.206-2.236) 0.524 1.086 (0.425-2.773) 0.863
CA125, elevated (vs normal) 61/68 2.898 (0.697-12.056) 0.144 2.152 (0.668-6.931) 0.199
Histologic grade, high (vs low) 63/75 4.401 (1.061-18.260) 0.041 4.341 (1.347-13.990) 0.014
DBC1, positive (vs negative) 54/75 4.277 (1.674-10.926) 0.002 2.811 (1.363-5.794) 0.005
BRCA1, positive (vs negative) 36/75 1.861 (1.007-3.438) 0.047 1.792 (1.032-3.110) 0.038
High-grade serous carcinomas (n = 63)
Age, y, ≥ 60 (vs < 60) 27/63 2.090 (1.119-3.900) 0.021 1.591 (0.907-2.791) 0.105
Stage, III & IV (vs I & II) 38/63 2.188 (1.080-4.434) 0.030 2.811 (1.464-5.399) 0.002
Tumor size, cm, > 10 (vs≤ 10) 15/63 0.736 (0.339-1.599) 0.439 0.860 (0.448-1.651) 0.650
LN metastasis, presence (vs absence) 15/63 1.520 (0.766-3.017) 0.232 1.841 (0.992-3.417) 0.053
Ascites, presence (vs absence) 26/63 1.395 (0.749-2.598) 0.294 1.340 (0.764-2.351) 0.308
Bilaterality, bilateral (vs unilateral) 36/63 1.300 (0.683-2.475) 0.424 1.452 (0.809–2.603) 0.211
CA19-9, elevated (vs normal) 6/49 0.726 (0.220-2.403) 0.600 1.344 (0.521-3.467) 0.541
CA125, elevated (vs normal) 53/58 2.220 (0.531-9.276) 0.275 1.443 (0.446-4.672) 0.540
DBC1, positive (vs negative) 50/63 4.031 (1.427-11.382) 0.008 2.540 (1.135-5.684) 0.023
BRCA1, positive (vs negative) 32/63 2.010 (1.063-3.803) 0.032 1.719 (0.973-3.038) 0.062
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(Figure 2). The patients with tumors expressing DBC1
had a 3.474-fold (P < 0.001, 95% confidence interval [95%
CI]; 1.684-7.166) greater risk of death and a 3.007-fold
(P < 0.001, 95% CI; 1.624-5.567) greater risk of relapse
or death. The five- and ten-year OS rates of the DBC1-
negative group were 78% and 73%, respectively, and were
only 42% and 36% in DBC1-positive group, respectively.
In addition, among the 83 patients who received adjuvantchemotherapy, DBC1 expression was significantly associ-
ated with shorter OS (P = 0.004, hazard ration [HR]; 3.625,
95% CI; 1.518-8.656) and RFS (P = 0.004, HR; 2.738, 95%
CI; 1.368-5.477). BRCA1 expression predicted shorter OS
(P = 0.005, HR; 2.263, 95% CI; 1.287-3.979) and RFS
(P = 0.002, HR; 2.254, 95% CI; 1.359-3.739) (Table 2).
When we did additional analysis in the subpopulation
of serous carcinomas, the factors significantly associated
with both OS and RFS by univariate analysis were the
Figure 2 Kaplan-Meier survival analyses in 104 overall ovarian carcinomas. Overall survival and relapse-free survival according to the tumor
stage (A), histologic grade (B), DBC1 expression (C), and BRCA1 expression (D).
Figure 3 Kaplan-Meier survival analyses in 75 ovarian serous carcinomas. Overall survival and relapse-free survival according to the tumor
stage (A), histologic grade (B), DBC1 expression (C), and BRCA1 expression (D).
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stage (OS; P = 0.021, RFS; P = 0.001), histologic grade
(OS; P = 0.041, RFS; P = 0.014), and DBC1 expression
(Log-rank, OS; P < 0.001, RFS; P = 0.003), and BRCA1 ex-
pression (Log-rank, OS; P = 0.043, RFS; P = 0.034) (Table 2)
(Figure 3). The patients who had DBC1-expressing serous
carcinoma had a 4.277-fold (P = 0.002, 95% CI; 1.674-
10.926) greater risk of death and its expression was signifi-
cantly associated with shorter RFS (P = 0.005, HR; 2.811,
95% CI; 1.363-5.794) (Figure 3C).
Among the 63 high-grade serous carcinomas, tumor
stage and the expression of DBC1 were significantly as-
sociated with both OS and RFS, and the age of patientsFigure 4 Kaplan-Meier survival analyses in 63 high-grade serous carc
tumor stage (A), DBC1 expression (B), and BRCA1 expression (C).and BRCA1 expression were significantly associated with
OS (Table 2) (Figure 4). The expression of DBC1 pre-
dicted a 4.031-fold (P = 0.008, 95% CI; 1.427-11.382)
greater risk of death and a 2.540-fold (P = 0.005, 95% CI;
1.135-5.684) greater risk of relapse or death of high-
grade serous carcinoma patients (Table 2). The OS rates
at five- and ten-years of DBC1-negative high-grade ser-
ous carcinomas were 85% and 64%, respectively, and
were 36% and 25% in DBC1-positive high-grade serous
carcinomas.
In the 20 cases of mucinous carcinomas, tumor stage
was significantly associated with shorter OS (Log-rank, P <
0.001) and RFS (Log-rank, P < 0.001). DBC1 expressioninomas. Overall survival and relapse-free survival according to the
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mucinous carcinoma patients (Log-rank, P = 0.060).
Expression of DBC1 is an independent prognostic
indicator of worse survival outcome in ovarian
carcinomas by multivariate analysis
The factors significantly associated with OS or RFS by
univariate analysis were included in the multivariate ana-
lysis. Because of data for CA125 was missing in 11 patients,
the CA125 level was not included in the multivariate ana-
lysis. The factors included in the multivariate analysis of
OS and RFS were age, tumor stage, lymph node metasta-
sis, presence of ascites, bilaterality of the tumor, histologic
grade, BRCA1 expression, and DBC1 expression. In 104
ovarian carcinomas, the factors significantly associated
with OS by multivariate analysis were age (P = 0.010),
tumor stage (P = 0.006), and DBC1 expression (P = 0.021).
The patients with tumors expressing DBC1 had a 2.423
fold (95% CI, 1.144-5.132) greater risk of death (Table 3).
Tumor stage (P < 0.001) and histologic grade (P = 0.007)
were the independent predictor of RFS. In addition, DBC1
expression was an independent predictor of OS (P = 0.026,
HR; 2.735, 95% CI; 1.128-6.634) among the 83 patients
who received adjuvant chemotherapy, as indicated by
multivariate analysis.
In the subpopulation of 75 serous carcinomas, the age of
the patients (P = 0.010) and DBC1 expression (P = 0.006)
were the independent predictors of OS. The expression of
DBC1 predicted a 3.757-fold (95% CI, 1.462-9.653) greater
risk of death. The factors significantly associated with
RFS in serous carcinoma were tumor stage (P < 0.001)Table 3 Multivariate Cox regression analyses for overall survi
Characteristics OS
HR (95% CI)
Overall ovarian carcinomasa
Age, y, ≥ 60 (vs < 60) 2.100 (1.191-3.702)
Stage, III & IV (vs I & II) 2.488 (1.295-4.780)
Histologic grade, high (vs low)
DBC1, positive (vs negative) 2.423 (1.144-5.132)
Serous carcinomasb
Age, y, ≥ 60 (vs < 60) 2.241 (1.212-4.144)
Stage, III & IV (vs I & II)
Histologic grade, high (vs low)
DBC1, positive (vs negative) 3.757 (1.462-9.653)
High-grade serous carcinomasc
Age, y, ≥ 60 (vs < 60) 1.961 (1.050-3.664)
Stage, III & IV (vs I & II)
DBC1, positive (vs negative) 3.828 (1.353-10.827)
aThe variables included in the multivariate analysis were age, tumor stage, lymph n
BRCA1 expression, and DBC1 expression. bThe variables included in the multivariate
expression. cThe variables included in the multivariate analysis were age, tumor staand histologic grade (P = 0.009) (Table 3). In addition, the
age of the patients (P = 0.035) and the expression of DBC1
(P = 0.011) were the independent predictor of OS in
high-grade serous carcinomas. The expression of DBC1
predicted a 3.828-fold (95% CI, 1.353-10.827) greater risk
of death of high-grade serous carcinoma patients (Table 3).
Discussion
This study has shown that immunohistochemical ex-
pression of DBC1 was significantly associated with ad-
vanced clinicopathological factors of ovarian carcinoma
such as higher tumor stage, latent distant metastasis,
platinum-resistance, elevated serum level of CA125, and
higher histologic grade. Moreover, DBC1 expression was
significantly associated with shorter survival of ovarian
carcinomas, especially in high-grade serous carcinomas. In
agreement with our results, increased expression of DBC1
has been reported as an indicator of poor prognosis of
gastric carcinoma [15], breast carcinoma [14], colorectal
carcinoma [9], esophageal carcinoma [20], clear cell renal
cell carcinoma [12], diffuse large B cell lymphoma [13],
and soft tissue sarcomas [13]. Nevertheless, there has been
no report investigating DBC1 expression in ovarian car-
cinomas. Therefore, this is the first report that examined
DBC1 expression in human ovarian tumors and suggests
that DBC1 expression might be usable as a prognostic in-
dicator for ovarian carcinoma patients.
DBC1 is interesting because of its putative role for the
inhibition of SIRT1 and has been suggested as tumor sup-
pressor [4,16,32]. However, there have been conflicting re-
ports regarding the role of DBC1 and SIRT1 in humanval and relapse-free survival in ovarian carcinomas
RFS
P HR (95% CI) P
0.010
0.006 3.426 (1.944-6.036) <0.001
3.023 (1.355-6.742) 0.007
0.021
0.010
3.023 (1.588-5.755) <0.001
4.818 (1.487-15.614) 0.009
0.006
0.035
2.488 (1.280-4.836) 0.007
0.011 2.059 (0.907-4.677) 0.084
ode metastasis, presence of ascites, bilaterality of the tumor, histologic grade,
analysis were age, tumor stage, histologic grade, BRCA1 expression, and DBC1
ge, BRCA1 expression, and DBC1 expression.
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and formed a positive-feedback loop with the c-Myc onco-
gene to stimulate tumorigenesis [33,34]. However, SIRT1
formed a negative-feedback loop with the c-Myc oncogene
in another report [35]. Moreover, the effects of the expres-
sion of DBC1 and SIRT1 in human malignant tumors var-
ied according to cell type [6,9,34,36,37]. The expression of
both DBC1 and SIRT1 predicted shorter survival of gastric
carcinoma [15], breast carcinoma [14], clear cell renal cell
carcinoma [12], soft-tissue sarcoma [13], and diffuse large
B cell lymphoma [13,16]. In colon cancer, DBC1 was over-
expressed in colorectal cancer and predicted shorter
survival of patients [9]. In contrast, another study reported
that SIRT1 expression is associated with poor prognosis
but DBC1 expression is associated with favorable progno-
sis of gastric cancer patients [36]. Although the expression
of SIRT1 was higher in ovarian carcinomas compared
with benign and borderline ovarian tumors, SIRT1 ex-
pression was associated favorable prognosis of ovarian
carcinoma patients [38]. Therefore, poor prognosis of
DBC1-expressing ovarian carcinoma might be related
to its inhibitory role for SIRT1. However, the relationship
between DBC1 and SIRT1 was been frequently dissociated
as shown in breast cancer [6]. Moreover, the knock-down
of DBC1 inhibited proliferation of liver cancer cells [37]
and suppressed invasiveness of gastric cancer cells [12].
Therefore, it may be likely that DBC1 has its own role
in tumorigenesis. DBC1 regulates BRCA1-mediated
function by binding to the BRCT domain in addition to
the suppression of SIRT1 expression [22]. In addition,
DBC1 inhibits senescence of premalignant cells by dis-
rupting the SUV39H1-SIRT1 complex. However, DBC1
showed a co-inhibitory effect for SUV39H1 and SIRT1
[8]. Therefore, there is a possibility that DBC1 may have
both tumorigenic and anti-tumorigenic roles [8,22]. Thus,
further study is needed to explore the exact role of DBC1
in tumorigenesis.
Because the expression of DBC1 was positively corre-
lated with higher tumor stage, higher tumor grade, and
latent metastasis of ovarian carcinoma, there is a possi-
bility that DBC1 might be involved in the acquisition of
invasive and metastatic potential. Recently, it has been
shown that DBC1 is associated with the invasive potential
of esophageal squamous cell carcinoma [20] and is im-
portant in the EMT of gastric carcinoma cells [12]. Espe-
cially, the oncogenic role of DBC1 was regulated by the
kinase effect of CK2α. CK2α phosphorylates DBC1 and
that is important for the induction of EMT. Knockdown
of DBC1 inhibited invasiveness of gastric cancer cells and
a point mutation at the phosphorylation site of DBC1 de-
creased the expression of MMP2, MMP9, snail, smad3,
and N-cadherin [12]. In addition, DBC1 induced anoikis
resistance that is important in tumor metastasis by activat-
ing the NFkB signaling pathway in breast cancer [17].The higher rate of distant metastatic relapse in DBC1-
expressing ovarian carcinomas raises the possibility that
DBC1 might be involved in the acquisition of resistance
for the postoperative chemotherapies. Among the 83 ovar-
ian carcinoma patients who received adjuvant chemother-
apy, the expression of DBC1 predicted shorter OS and
RFS. In addition, among the 55 high-grade serous carcin-
oma patients who received adjuvant chemotherapy, DBC1
expression was significantly associated with poor OS (P =
014, HR; 4.484, 95% CI; 1.362-14.758) and RFS (P = 0.042,
HR; 2.471, 95% CI; 1.035-5.899). Moreover, DBC1 ex-
pression correlated with platinum-resistance. All serous
carcinoma patients having tumors with DBC1 expression
(100%, 16/16) showed platinum-resistance. In contrast,
62% (32/48) of DBC1-negative serous carcinoma patients
showed platinum-resistance. Similarly, DBC1 expression
was associated with frequent relapse and shorter survival
of breast carcinoma patients who received adjuvant chemo-
therapy [14]. Although it did not reach statistical sig-
nificance, lower expression of DBC1 would indicate a
favorable pathological response to chemotherapy [39].
Because DBC1 is involved in the inhibition of BRCA1
[22] and BRCA1/2 status is important in the develop-
ment and progression of ovarian carcinomas, we investi-
gated the immunohistochemical expression of BRCA1 in
ovarian carcinomas. Although we could evaluate the im-
munohistochemical expression of BRCA1, a recent report
has shown that there is a strong correlation between the
immunohistochemical expression and molecular events in
BRCA1 [30]. In this study, BRCA1 expression was signifi-
cantly associated with latent distant metastasis, platinum-
resistance, and higher histologic grade. In addition, in
agreement with previous reports [24,40,41], we have dem-
onstrated that low-expression of BRCA1 is associated with
poor survival of ovarian carcinomas. The reason why the
patients with defective BRCA1/2 have a longer survival
times compared with BRCA1/2 wild-type carcinomas is
related with BRCA1/2-defects in cells making them more
sensitive to conventional chemotherapy, especially to
the platinum-based chemotherapy [23,24,42]. Our re-
sults have also shown that BRCA1-positivity is significantly
associated with increased platinum-resistance (Table 1).
Thereby, several therapeutic applications according to the
BRCA1/2 status are under evaluation. Recently, PARP in-
hibitors have been reported as being specifically applicable
to the treatment of BRCA1/2-defective cancers [43,44]. In
our study, the expression of DBC1 and BRCA1 showed
positive correlation and the expressions of both molecules
was related with platinum-resistance and shorter survival
of ovarian carcinoma patients. Based on the inhibitory role
of DBC1 for the BRCA1 [22], the co-expressing pattern of
these two molecules in the poor prognostic group of
ovarian carcinomas is questionable and paradoxical as
BRCA1/2 defective cancers are more susceptible to therapy
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roles of DBC1 in tumorigenesis and further study is needed.
Another possible oncogenic role of DBC1 might be re-
lated with its role in the co-activation of nuclear recep-
tors [18,19,21]. DBC1 co-activates estrogen receptor and
androgen receptor (AR), which can be ligand-dependent
or ligand-independent [18,19,21]. Although there was no
significant correlation between the expression of DBC1
and estrogen receptor in breast carcinoma [14], signifi-
cant positive correlations between the expression of
DBC1 and AR have been reported in clear cell renal cell
carcinoma [12] and diffuse large B cell lymphoma [11].
Especially, the expression of both DBC1 and AR pre-
dicted shorter survival of cancer patients [11,12,14-16].
Additionally, ovarian epithelium expressing AR and an-
drogen induced proliferation of ovarian epithelial cells
and inhibited cell death [45]. In ovarian high-grade ser-
ous carcinomas, immunohistochemical expression of AR
correlated with the S-phase fraction and AR expression
decreased with platinum-based chemotherapy [46]. These
reports suggest that AR is involved in the ovarian carcino-
genesis. Therefore, there is a possibility that DBC1 is in-
volved in ovarian tumorigenesis with the interaction with
AR and further study is needed.
Ovarian carcinomas are a heterogeneous group of can-
cers that have origins and pathogenic profiles that differ
according to histologic types. Therefore, when we con-
sider the prognostic impact of DBC1 expression according
to histologic types of ovarian carcinoma, DBC1 predicted
shorter survival in serous carcinomas, especially in high-
grade serous carcinomas. The 10-years OS rate was only
25% in DBC1-positive cases, and was 64% in DBC1-
negative cases. In mucinous carcinomas, DBC1 expression
was very low compared with other subtypes of ovarian
carcinomas (15% in mucinous carcinoma, 72% in serous
carcinoma, and 100% in endometrioid carcinoma). How-
ever, despite the low frequency of DBC1-positivity and the
small number of cases of mucinous carcinoma, DBC1
expression showed borderline significance in OS analysis
(Log-rank, P = 0.060). The 10-years OS rates of DBC1-
negative and DBC1-positive mucinous carcinomas were
76% and 33%, respectively. In line with our results, DBC1
expression was associated with a higher nuclear grade of
breast carcinoma [39]. Therefore, although the expression
rate of DBC1 differs according to the histologic types, our
result suggests that DBC1 expression might be involved in
the progression of ovarian carcinomas, regardless of histo-
logic types. However, further study with a larger group of
ovarian carcinoma is needed to clarify the role of DBC1 in
ovarian carcinomas.
Conclusions
In conclusion, to our knowledge, this is the first study to
show that DBC1 is commonly expressed in ovariancarcinomas and its expression is predictive of prognosis
of ovarian carcinoma patients, especially in high-grade
serous carcinomas and possibly in mucinous carcinomas.
In addition, DBC1 expression was significantly associated
with BRCA1 expression and their expressions were related
with resistance to platinum-based chemotherapy and poor
prognosis of ovarian carcinoma patients. Therefore, these
results indicate that the expression of DBC1 and BRCA1
might be used for the prediction of prognosis of ovarian
carcinomas. Especially, DBC1 expression might be helpful
for the prediction of the prognosis of high-grade serous
carcinomas. In addition, these findings suggest that DBC1
and BRCA1could be potential therapeutic targets for the
treatment of ovarian carcinomas according to the expres-
sion status of DBC1 and BRCA1. However, because of the
limited number of non-serous cases of ovarian carcinoma
subtypes in this study, further study with more cases is
needed to clarify the roles of DBC1 and BRCA1 in various
histologic subtypes of ovarian carcinomas.
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